Proliant Health & Biologicals
a two-decade albumin manufacturer that commercially launched AlbufreeDX on June 24, 2026 — a precision-fermentation fungal-cell-line animal-free rHA (purity ≥98%, total protein ≥90% dry basis) for IVD/diagnostic applications, with planned extensions AlbufreeTX (cell culture) and AlbufreeCGT (cell/gene therapy);…
- Country
- United States
AlbufreeDX commercial launch Jun 24, 2026; IVDR compliance; planned AlbufreeTX/CGT extensions
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.